Henrik from Luxembourg

Registered at the short selling broker Capital, 2 minutes ago.

» Try Capital you too
67.7% of retail investor accounts lose money when trading CFDs with Capital.
Don't show again

Novartis AG (NVS) shares information

Novartis AG – ADR


24h Change

0.30 %

NVS

Live rate: Market closed

Stock data per Friday 22 Oct, 2021

NVS
NEW YORK STOCK EXCHANGE INC.
84.67
84.55
84.92
0.25 (+ 0.30%)
US Market is closed

Live Stock price in graph for Novartis AG – ADR (NVS)

  • Latest Volume

    1,505,336 (-30.48 %)

  • Volume prev. day

    2,165,193

  • Avg. daily volume

    2,092,488

  • Market cap

    206,731,024,526

  • P/E ratio

    21.55

  • Today high

    84.92 USD

  • Today low

    84.37 USD

  • 52 week high

    95.17 USD

  • 52 week low

    74.07 USD

  • YTD Change

    n/a

Quick links

 

Latest news about Novartis AG – ADR

Below you can find the most recent news posts about Novartis AG – ADR, primarily from US and UK based news sources.

Psychotropic Drug Market to Witness Stunning Growth | Sanofi, Biocon, Lupin,Novartis

Saturday, 23 October 2021, 07:01:45
Advance Market Analytics published a new research publication on Psychotropic Drug Market Insights, to 2026 with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities
— OpenPR


CIBC Private Wealth Group LLC Has $32.95 Million Holdings in Novartis AG (NYSE:NVS)

Friday, 22 October 2021, 18:20:42
CIBC Private Wealth Group LLC boosted its stake in Novartis AG (NYSE:NVS) by 3.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 361,185 shares of the companys stock after buying an additional 10,886 shares during the quarter. CIBC Private []
— Dakota Financial News


Onychomycosis Drugs Market 2021 Growing Demand, Size and Business Outlook – Pfizer, Novartis, Johnson & Johnson, Bausch Health, Bayer, Galderma

Friday, 22 October 2021, 11:33:01
The “Onychomycosis Drugs” Market report offers qualitative and quantitative insights and a detailed analysis of market size & growth rate for all possible segments in the market. The Global Onychomycosis Drugs Industry presents a market overview, product details, classification, and
— OpenPR


ESR1 Mutated Metastatic Breast Cancer Market Anticipated to Propel with an Escalated CAGR of 4.48% for the Study Period 2018-30, Investigates DelveInsight

Thursday, 21 October 2021, 18:30:00
LAS VEGAS , Oct. 21, 2021 /PRNewswire/ — DelveInsight”s ESR1 Mutated Metastatic Breast Cancer Market Insights report proffers a detailed comprehension of ESR1 Mutated Metastatic Breast Cancer market size by treatment, epidemiology, emerging therapies, current and forecasted ESR1 Mutated Metastatic Breast Cancer market size from 2018 to 2030 segmented into 7MM (the USA , EU5 (the UK, Italy , Spain , France , and Germany ), and Japan ). Some of the key highlights from the ESR1 Mutated Metastatic Breast Cancer Market Report: According to an analysis by DelveInsight, the market size for ESR1 Mutated Metastatic Breast Cancer was USD 919 million in 2020 in the United States . As per DelveInsight”s estimate, the ESR1 Mutated Metastatic Breast Cancer market is anticipated to be inclined towards a positive shift due to various factors like the launch of upcoming therapies and an increase in cancer prevalence. The ESR1 Mutated Metastatic Breast Cancer market size is set to show an extensive jump by the end of 2030, at a CAGR of 4.48% from 20182030.
— Benzinga


Neuroendocrine Tumor Treatment Market Rapid Growth with Key Focus on Global 2021-2028 | Pfizer, Novartis AG, Ispen, Tarveda Therapeutics, Progenics Pharmaceuticals,

Thursday, 21 October 2021, 16:44:31
The Latest research study released by CMI Global Neuroendocrine Tumor Treatment Market with 100+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market development, landscape, technologies, drivers,
— OpenPR


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have NVS available or trade one of the many other CFD stocks they have.
Risk warning: 67.7% of retail investor accounts lose money when trading CFDs with Capital.